Pssst. Wanna buy some chemo drugs?
A new trend in pharmaceutical sales has raised concerns over ethics and patient safety, as companies buy up critical cancer drugs in short supply and attempt to resell them at huge markups.
Rather than operate by the dark of night on street corners, these drug dealers work in broad daylight using fax, telephone and e-mail to deluge hospitals with offers.
Experts say the so-called “gray market” is not illegal and could even be poised to surge further after US President Barack Obama issued an executive order that tried to fix the problem, but may have just opened a larger loophole.
“These are a number of very small firms that have popped up out of nowhere. Most of them are relatively new,” said Thomas Smith, director of palliative medicine at Johns Hopkins Medical Institutions. “It happens in every other market, we just don’t expect it to happen in pharmaceuticals for cancer treatment.”
Fifty-six percent of the 549 hospitals surveyed by the non-profit Institute for Safe Medication Practices (ISMP) earlier this year said they received daily solicitations from gray market vendors “to purchase medications no longer available through the manufacturer or usual wholesaler.”
Fifty-two percent admitted to buying one or more drugs from gray market vendors in the past two years, as manufacturers halted production of some generic drugs because they were no longer profitable.
“I would like to know why hospitals can’t get these products, but the ‘scalpers’ can. It is unreal to have to deal with ‘scalpers’ in healthcare,” said one survey respondent whose name was withheld by ISMP.
Drug prices ranged from 650 percent to 4,000 percent over the usual cost, said the survey, which referred to all kinds of pharmaceuticals, not just cancer drugs.
Prescription drug shortages in the US nearly tripled from 2005 to last year, according to the Department of Health and Human Services.
Just why drugs are falling out of production, particularly in cancer care, has to do with the extremely low price of generic medicines and the profit incentive that drives cancer doctors to prescribe costlier medications.
Oncologists get a portion of their pay by buying drugs wholesale and billing the government’s Medicare behemoth for reimbursement, a practice that ended up paying US doctors more than they spent on the drugs by US$1.6 billion a year.
A law signed by former US president George W. Bush in 2003 tried to clamp down on inflated billing by ordering Medicare to pay doctors based on a drug’s average selling price, plus 6 percent.
Prices were also prohibited from rising more than 6 percent every six months.
That limited the market’s ability to respond to a shortage of a generic drug by increasing its price. Manufacturers were faced with limited demand and a 90 percent price drop for a generic drug. And cancer doctors were faced with a deep cut to their bottom line.
“Why use paclitaxel [and receive 6 percent of US$312] when you can use Abraxane [for 6 percent of US$5,824]?” Smith wrote.
The rise of the gray market, viewed by experts as an unintended consequence of the Bush move, has sparked new worries about the safety of the drugs being re-sold, or that errors could be made in dosing adjustments if hospitals seek alternate medications.
It remains unknown exactly how many gray market drug vendors are out there. Five are being investigated by Congressman Elijah Cummings for offering breast, ovarian, colon and lung cancer drugs at vastly inflated prices.
Only one of those five, Allied Medical — which was singled out for offering a leukemia drug at more than US$990 A vial when the usual price was US$12 — returned a request for comment, but refused to grant an on-the-record interview.
“Recent media attention on prescription drug shortages highlights the vital role that Allied Medical Supply and other companies play to ensure that hospitals and patients have the medicines they need when they need them,” it said in a statement.
Obama last month signed an executive order to require drug manufacturers to “provide adequate advance notice of manufacturing discontinuances that could lead to shortages of drugs that are life supporting or life sustaining.”
Oncologist James Speyer, medical director of the Clinical Cancer Center at New York University Langone Medical Center, applauded the move as an important first step.
However, he said: “I don’t think it is going to address every part of the problem. I believe, as do many colleagues, that the amount of money a company can charge for the drug plays a real role here.”
Europe has avoided the problem because oncologists do not have the incentive to administer more expensive drugs, and generics cost more while brand names generally cost 20 to 40 percent less than in the US.
One solution could involve the US government partnering with cancer drug manufacturers the way it does with makers of low-cost, unprofitable vaccines, to ensure companies are paid enough to supply the market, Smith said.
“Manufacturers won’t make the drugs unless they have a stable demand and a stable profit,” he said.
ROCKY RELATIONS: The figures on residents come as Chinese tourist numbers drop following Beijing’s warnings to avoid traveling to Japan The number of Chinese residents in Japan has continued to rise, even as ties between the two countries have become increasingly fractious, data released on Friday showed. As of the end of December last year, the number of Chinese residents had increased by 6.5 percent from the previous year to 930,428. Chinese people accounted for 22.6 percent of all foreign residents in Japan, making them by far the largest group, Japanese Ministry of Justice data showed. Beijing has criticized Tokyo in increasingly strident terms since Japanese Prime Minister Sanae Takaichi last year suggested that a military conflict around Taiwan could
A retired US colonel behind a privately financed rocket launch site in the Dominican Republic sees the project as a response to China’s dominance of the space race in Latin America. Florida-based Launch on Demand is slated to begin building a US$600 million facility in a remote region near the border with Haiti late this year. The project is designed to meet surging demand for the heavy-lift rockets needed to put clusters of satellites into orbit. It is also an answer to China’s growing presence in the region, said CEO Burton Catledge, a former commander of the US Air Force’s 45th Operations
Germany is considering Australia’s Ghost Bat robot fighter as it looks to select a combat drone to modernize its air force, German Minister of Defense Boris Pistorius said yesterday. Germany has said it wants to field hundreds of uncrewed fighter jets by 2029, and would make a decision soon as it considers a range of German, European and US projects developing so-called “collaborative combat aircraft.” Australia has said it will integrate the Ghost Bat, jointly developed by Boeing Australia and the Royal Australian Air Force, into its military after a successful weapons test last year. After inspecting the Ghost Bat in Queensland yesterday,
A pro-Iran hacking group claimed to breach FBI Director Kash Patel’s personal e-mail inbox and posted some of the contents online. The e-mails provided by the hacking group include travel details, correspondence with leasing agents in Washington and global entry, and loyalty account numbers. The e-mail address the hackers claim to have compromised has been previously tied to Patel’s personal details, and the leaked e-mails contain photos of Patel and others, in addition to correspondence with family members and colleagues. “The FBI is aware of malicious actors targeting Director Patel’s personal email information,” the agency said in a statement on
RSS